Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Wilcox

Showing results (11-20 of 74) with videos related to

Pageof 8
Sort By:
The New England Journal of Medicine|April 20, 2017
Bezlotoxumab and Recurrent Clostridium difficile InfectionMark Wilcox, Mary-Beth Dorr, Alison Pedley
Lancet (London, England)|March 28, 2006
Measurement of toxin production by Clostridium difficileJane Freeman, Warren Fawley, Simon Baines, et al.
Expert Opinion on Emerging Drugs|October 9, 2019
Emerging drugs for treating methicillin-resistant <i>Staphylococcus aureus</i>Matteo Bassetti, Alessandro Russo, Alessia Carnelutti, et al.
Journal of Clinical Microbiology|August 28, 2009
Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methodsKerrie Eastwood, Patrick Else, André Charlett, et al.
Journal of Clinical Medicine|February 15, 2022
Frozen Blastocyst Embryo Transfer: Comparison of Protocols and Factors Influencing OutcomeAikaterini Eleftheriadou, Abraham Francis, Mark Wilcox, et al.
Journal of Medical Microbiology|May 16, 2019
Serum IgE and IgG reactivity to Aspergillus recombinant antigens in patients with cystic fibrosisNada S Alghamdi, Richard Barton, Mark Wilcox, et al.
Respiratory Medicine|May 31, 2021
Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trialManjunath P Pai, Mark Wilcox, Surya Chitra, et al.
Expert Review of Anti-Infective Therapy|December 21, 2012
Epidemiology, diagnosis and treatment of Clostridium difficile infectionMatteo Bassetti, Giovanni Villa, Davide Pecori, et al.
BMJ (Clinical Research Ed.)|February 23, 2008
Improving early management of bloodstream infection: a quality improvement projectJane Minton, James Clayton, Jonathan Sandoe, et al.
BMC Infectious Diseases|April 17, 2015
A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infectionsRichard Vickers, Neil Robinson, Emma Best, et al.
Pageof 8

Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
The New England Journal of Medicine|April 20, 2017
Bezlotoxumab and Recurrent Clostridium difficile InfectionMark Wilcox, Mary-Beth Dorr, Alison Pedley
Lancet (London, England)|March 28, 2006
Measurement of toxin production by Clostridium difficileJane Freeman, Warren Fawley, Simon Baines, et al.
Expert Opinion on Emerging Drugs|October 9, 2019
Emerging drugs for treating methicillin-resistant <i>Staphylococcus aureus</i>Matteo Bassetti, Alessandro Russo, Alessia Carnelutti, et al.
Journal of Clinical Microbiology|August 28, 2009
Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methodsKerrie Eastwood, Patrick Else, André Charlett, et al.
Journal of Clinical Medicine|February 15, 2022
Frozen Blastocyst Embryo Transfer: Comparison of Protocols and Factors Influencing OutcomeAikaterini Eleftheriadou, Abraham Francis, Mark Wilcox, et al.
Journal of Medical Microbiology|May 16, 2019
Serum IgE and IgG reactivity to Aspergillus recombinant antigens in patients with cystic fibrosisNada S Alghamdi, Richard Barton, Mark Wilcox, et al.
Respiratory Medicine|May 31, 2021
Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trialManjunath P Pai, Mark Wilcox, Surya Chitra, et al.
Expert Review of Anti-Infective Therapy|December 21, 2012
Epidemiology, diagnosis and treatment of Clostridium difficile infectionMatteo Bassetti, Giovanni Villa, Davide Pecori, et al.
BMJ (Clinical Research Ed.)|February 23, 2008
Improving early management of bloodstream infection: a quality improvement projectJane Minton, James Clayton, Jonathan Sandoe, et al.
BMC Infectious Diseases|April 17, 2015
A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infectionsRichard Vickers, Neil Robinson, Emma Best, et al.
Pageof 8